Copyright: ©Author(s) 2026.
World J Exp Med. Jun 20, 2026; 16(2): 119440
Published online Jun 20, 2026. doi: 10.5493/wjem.v16.i2.119440
Published online Jun 20, 2026. doi: 10.5493/wjem.v16.i2.119440
Table 1 Baseline characteristics of the study population, mean ± SD/n (%)
| Variable | TII/TID, n = 52 | TII + TID, n = 48 | Total, n = 100 | P value |
| Age (year) | 26.08 ± 14.89 | 29.79 ± 10.69 | 27.86 ± 13.12 | 0.158 |
| Systolic BP (mmHg) | 125.10 ± 24.87 | 133.74 ± 30.75 | 129.24 ± 28.03 | 0.132 |
| Diastolic BP (mmHg) | 74.30 ± 15.92 | 80.28 ± 17.65 | 77.17 ± 16.95 | 0.084 |
| Urine protein (g) | 3.35 ± 4.52 | 2.97 ± 2.71 | 3.17 ± 3.75 | 0.615 |
| Serum creatinine (µmol/L) | 121.27 ± 162.65 | 126.75 ± 120.38 | 123.92 ± 143.02 | 0.852 |
| eGFR (mL/minute/1.73 m2) | 98.21 ± 52.71 | 77.67 ± 37.37 | 88.35 ± 46.91 | 0.028 |
| Hemoglobin (g/dL) | 10.51 ± 2.05 | 13.87 ± 16.90 | 12.12 ± 11.85 | 0.161 |
| WBC count (× 109/L) | 7.17 ± 3.89 | 7.04 ± 4.02 | 7.10 ± 3.93 | 0.888 |
| Platelet count (× 109/L) | 230.67 ± 135.81 | 236.26 ± 150.98 | 233.53 ± 142.94 | 0.859 |
| PTH (pmol/L) | 8.09 ± 14.35 | 9.33 ± 10.09 | 8.72 ± 12.30 | 0.674 |
| C3 (g/L) | 0.70 ± 0.46 | 0.67 ± 0.30 | 0.69 ± 0.39 | 0.648 |
| C4 (g/L) | 0.17 ± 0.15 | 0.14 ± 0.09 | 0.16 ± 0.13 | 0.248 |
| Total protein in serum (g/L) | 52.37 ± 17.04 | 51.50 ± 16.02 | 51.93 ± 16.42 | 0.825 |
| Albumin in serum (g/L) | 28.50 ± 7.59 | 27.66 ± 7.06 | 28.09 ± 7.32 | 0.571 |
| Total cholesterol (mmol/L) | 4.75 ± 4.32 | 4.70 ± 2.36 | 4.72 ± 3.44 | 0.951 |
| LDL-C (mmol/L) | 1.78 ± 1.82 | 3.01 ± 1.88 | 2.40 ± 1.94 | 0.006 |
| HDL-C (mmol/L) | 0.91 ± 0.86 | 0.94 ± 0.56 | 0.93 ± 0.72 | 0.843 |
| TG (mmol/L) | 1.32 ± 0.96 | 1.57 ± 0.86 | 1.45 ± 0.91 | 0.253 |
| HA1C at diagnosis (%) | 3.74 ± 3.00 | 4.70 ± 1.61 | 4.19 ± 2.48 | 0.069 |
| Sodium (mmol/L) | 137.80 ± 4.06 | 135.53 ± 5.72 | 136.65 ± 5.07 | 0.058 |
| Potassium (mmol/L) | 4.23 ± 0.60 | 4.42 ± 0.70 | 4.32 ± 0.65 | 0.226 |
| Calcium (mmol/L) | 2.05 ± 0.49 | 2.09 ± 0.24 | 2.07 ± 0.39 | 0.626 |
| Phosphorus (mmol/L) | 1.30 ± 0.65 | 1.22 ± 0.38 | 1.26 ± 0.54 | 0.517 |
| Uric acid (µmol/L) | 313.23 ± 193.36 | 383.15 ± 178.02 | 349.14 ± 187.68 | 0.11 |
| CRP (mg/L) | 10.98 ± 17.35 | 12.85 ± 28.66 | 11.88 ± 23.40 | 0.703 |
| ANA | 1.20 ± 0.40 | 1.07 ± 0.26 | 1.14 ± 0.35 | 0.077 |
| ANA titer or dilution | 621.71 ± 584.77 | 687.78 ± 492.12 | 655.21 ± 536.93 | 0.608 |
| Anti ds-DNA | 1.24 ± 0.65 | 1.45 ± 0.54 | 1.34 ± 0.61 | 0.085 |
| Anti ds-DNA titer | 215.29 ± 512.00 | 125.32 ± 355.03 | 172.14 ± 443.78 | 0.319 |
| Anti SM antibody | 16.59 ± 81.41 | 1.92 ± 7.11 | 9.15 ± 57.43 | 0.285 |
| Anti RNP antibody positivity | 0.69 ± 4.06 | 0.00 ± 0.00 | 0.34 ± 2.85 | 0.314 |
| Modified NIH Activity score | 3.13 ± 3.18 | 6.17 ± 3.90 | 4.59 ± 3.84 | 0 |
| Chronicity score | 1.85 ± 2.44 | 4.21 ± 1.74 | 2.98 ± 2.43 | 0 |
| Gender | ||||
| Female | 43 (82.7) | 41 (85.4) | 84 (84.0) | 0.71 |
| Male | 9 (17.3) | 7 (14.6) | 16 (16.0) | |
| Class | ||||
| I/II | 7 (13.5) | 1 (2.1) | 8 (8.0) | 0.024a |
| III | 8 (15.4) | 17 (35.4) | 25 (25.0) | |
| III and V | 5 (9.6) | 8 (16.7) | 13 (13.0) | |
| IV | 11 (21.2) | 7 (14.6) | 18 (18.0) | |
| IV and V | 8 (15.4) | 10 (20.8) | 18 (18.0) | |
| V/VI | 13 (25.0) | 5 (10.4) | 18 (18.0) | |
| Hypertension | ||||
| Yes | 33 (64.7) | 38 (79.2) | 71 (71.7) | 0.11 |
| No | 18 (35.3) | 10 (20.8) | 28 (28.3) | |
| DM | ||||
| Yes | 6 (12.0) | 9 (19.1) | 15 (15.5) | 0.33 |
| No | 44 (88.0) | 38 (80.9) | 82 (84.5) | |
| Induction drug: CYC | 15 (28.8) | 9 (18.8) | 24 (24.0) | 0.292 |
| MMF | 36 (69.2) | 39 (81.3) | 75 (75.0) | |
| MMF + CYC | 1 (1.9) | 0 (0.0) | 1 (1.0) | |
| Maintenance (yes) | 5 (9.6) | 2 (4.2) | 7 (7.0) | 0.502 |
| MMF (maintenance) | 38 (73.1) | 42 (87.5) | 80 (80.0) | |
| Azathioprine (AZA) | 3 (5.8) | 3 (6.3) | 6 (6.0) | |
| MMF + CNI | 3 (5.8) | 1 (2.1) | 4 (4.0) | |
| MMF or AZA | 1 (1.9) | 0 (0.0) | 1 (1.0) | |
| MMF+ AZA + CNI | 1 (1.9) | 0 (0.0) | 1 (1.0) | |
| Podocyte effacement ≥ 50 | 27 (52.9) | 22 (46.8) | 49 (50.0) | 0.083 |
| Podocyte effacement < 50 | 14 (27.5) | 7 (14.9) | 21 (21.4) | |
| No comment or not done | 10 (19.6) | 18 (38.3) | 28 (28.6) | |
| EM mesangium deposits | 3 (6.0) | 14 (30.4) | 17 (17.7) | 0.007a |
| EM | ||||
| Yes | 26 (52.0) | 16 (34.8) | 42 (43.8) | |
| No | 21 (42.0) | 16 (34.8) | 37 (38.5) | |
| Full house | 30 (63.8) | 21 (52.5) | 51 (58.6) | 0.285 |
| Partial | 17 (36.2) | 19 (47.5) | 36 (41.4) | |
| Statin | ||||
| Yes | 17 (34.0) | 17 (36.2) | 34 (35.1) | 0.823 |
| No | 33 (66.0) | 30 (63.8) | 63 (64.9) | |
| ACEI | ||||
| Yes | 24 (55.8) | 27 (64.3) | 51 (60.0) | 0.425 |
| No | 19 (44.2) | 15 (35.7) | 34 (40.0) | |
| ARB | ||||
| Yes | 22 (47.8) | 23 (56.1) | 45 (51.7) | 0.441 |
| No | 24 (52.2) | 18 (43.9) | 42 (48.3) | |
| SGLT-2 | ||||
| Yes | 4 (7.8) | 4 (8.5) | 8 (8.2) | 0.904 |
| No | 47 (92.2) | 43 (91.5) | 90 (91.8) |
- Citation: Khalil MAM, Sadagah NM, Mahmood HHK, Alrowaie F, Almansour AM, Alghamdi RMH, Alghamdi L, A Al-Ghamdi R, Elgadi A, Al-Qurashi SH. Forgotten compartment: Impact of tubulointerstitial inflammation and damage on renal outcomes in lupus nephritis from Saudi Arabia. World J Exp Med 2026; 16(2): 119440
- URL: https://www.wjgnet.com/2220-315x/full/v16/i2/119440.htm
- DOI: https://dx.doi.org/10.5493/wjem.v16.i2.119440